NCT07624838 2026-06-03Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in SpainGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaRecruiting100 enrolled